NVS241220P100000
- 3.40
- +0.80+30.77%
Novartis AG Newsroom
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Sanofi: Kress Was the CEO of MorphoSys From 2019 Until It Was Acquired by Novartis in 2024
Novartis will close MorphoSys's factories in Germany and the USA.
According to Reuters on December 19, the Swiss pharmaceutical group Novartis announced on Thursday that it will close the German Biotechnology company MorphoSys's factories in Germany and the USA, acquired earlier this year, affecting approximately 330 positions. A company spokesperson stated that the plan is to exit the factories in Munich and Boston by the end of 2025 and to consolidate all portfolio activities into Novartis.
Market Chatter: Novartis to Close MorphoSys Sites, Affecting 330 Jobs
Novartis AG (NOVN) Gets a Sell From Barclays
The prospects of European Medical Care stocks are complex, with USA policies and new drug trial results being the key factors.
After falling from a high position in the last few months of 2024, European Medical Care stocks face the risks of US politics and the results of high-risk new drug trials in the new year.
CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
BioAge Stock Advances 14% On Novartis Research Collaboration
BioAge Labs Says It Is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Alcon a Top Pick for 2025 at Needham on Upcoming Product Launches
NVS Vs. LLY: Which Stock Should Value Investors Buy Now?
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Swiss Equities an Overweight Pick Next Year -- Market Talk
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Announces Target Price $125
Monte Rosa Closes Global License Agreement With Novartis
Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
Raymond James, Cantor Bullish on UniQure Following FDA Update
Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment